Home | News | Find a Doctor | Ask a Question | Free

Where is the page?


#1

Where’s the original of the information about discontinuing the TRC. Just some guy put it onto his blog. Where the hell is the original? I can’t find it anywhere.

http://www.google.com/search?hl=en&safe=off&rls=com.microsoft%3Aen-gb%3AIE-SearchBox&rlz=1I7GGLG&q="These+data+are+consistent+with+the+earlier+data+reported+last+September+and+the+hypothesis"

None of these links contains the information:
http://www.intercytex.com/icx/news/releases/2008/2008-03-18/
http://www.intercytex.com/icx/investors/rep/rep2008/2008-03-18/2008-03-18.pdf

So did it disapear or was it ever there?


#2

http://www.intercytex.com/icx/news/releases/2008/2008-03-18/

Just checking it out now.

This is from their website:

ICX-TRC

Product description

ICX-TRC consists of a suspension of autologous dermal papilla (DP) cells. These cells are able to stimulate the generation of new hairs when injected into the scalp in close proximity to the epidermal cells which generate the hair.

It is intended that ICX-TRC will be used by specialists in hair transplant centres, dermatologists and plastic surgeons to treat patients with hair thinning or hair loss.

Clinical development

We have now completed the treatment phase of our Phase II study, being conducted by Dr Bessam Farjo in Manchester, to optimise the delivery of the DP cells.

In this study, hair counts are obtained by shaving and photographing a small section of scalp, injecting it and then applying a specialised image analysis system to provide a total hair count. All 19 subjects in the trial have now been treated using a range of injection and scalp pre-stimulation techniques; the first 6 subjects were injected without stimulation of the scalp. In the remaining 13 the resident hair producing (epithelial) cells were stimulated at the time of delivery of the DP cells.

11 subjects have now passed the 24-week time point since treatment and specialised image analysis at this time point showed:

• Of the group of 6 patients without stimulation of the scalp, 3 had an increased hair count and
two had a reduced hair count; one has been lost to follow-up.

• Of the 5 subjects with pre-treatment scalp stimulation, all had increased hair count at 12 weeks
and the 3 who were evaluable at 24 weeks all had an increased hair count at that time point.

.
These data are consistent with the earlier data reported last September and the hypothesis that new hair production is improved by pre-stimulation of the scalp, leading to an interaction between the injected cells and the resident hair producing cells.

24 week data on all subjects in the trial will be available in September 2008 and at the end of the trial photographic data will be analysed from a much larger area of treated scalp on all subjects at 48 weeks.

Commercial opportunity

ICX-TRC overcomes one of the principal drawbacks of conventional transplants which is that the outcome is limited by the amount of donor hair available. By using the Intercytex cell therapy technique almost limitless hair regeneration is possible in a less invasive procedure. Furthermore, treatment can commence early on in the hair loss process with retreatment available in subsequent years. The barrier to commercial success for ICX-TRC is relatively low, being the ability to increase hair count in transplanted or thinning areas.

We believe the continued development of ICX-TRC would best be carried out in partnership with a specialist in the aesthetics field. We do not intend to finance the continuation of clinical and commercial development of ICX-TRC beyond the current Phase II trial and shall seek to sign a partner when we have the complete data package from this trial. Intercytex has granted Bosley, the largest chain of hair transplant clinics in the US, an option to negotiate distribution rights to the product.

Intellectual Property
We have split our cell delivery patent application into three separate applications in the US reflecting additional techniques that are being developed. We have also filed a patent application relating to our
observation that epidermal stimulation pre-treatment appears to enhance hair follicle formation.

Two other previously filed patent applications relating to the method of culturing the dermal papilla cells have been published and are undergoing international examination.

Post reply


#3

I wish I could use that as my avatar


#4

I’m sorry guys but this is what I see on the page http://www.intercytex.com/icx/news/releases/2008/2008-03-18/

DownloadsContact UsAlert ServicePrint this page Site Search

Press Releases    

Results for the year ended 31 December 2007
18th March 2008

Intercytex Group plc
Positive clinical data continues to be generated across product portfolio

Intercytex Group plc (LSE: ICX) today announces its results for the year ended 31 December 2007. The Company also reports new clinical data on all of its regenerative medicine products; VAVELTA®, ICX-PRO, ICX-SKN and ICX-TRC.

Intercytex is the leading developer of regenerative medicine products to restore skin and hair. The Company uses its fully integrated cell technology platform to develop living, human cell-based products, at commercially viable scale in attractive markets.

PRODUCT HIGHLIGHTS

VAVELTA® - facial rejuvenation and skin damage

Positive responses with some exceptional results being generated from field trials of VAVELTA conducted by the Clinical Practice Group
High clinician and patient satisfaction scores from three/six month data in facial rejuvenation and acne scarring Phase II trials - underlines potential of VAVELTA in rapidly growing markets
First revenues mid-2008 with commercial roll-out in UK during H2 2008
Phase II trial in burns contractures open to recruitment
ICX-PRO (cyzact®) - chronic wounds

Phase II data from diabetic foot ulcer trial of ICX-PRO shows very high healing rates
Recruitment in Phase III trial in venous leg ulcers on track for completion in Q2 with over 350 patients randomised to date, in line with previous guidance.
ICX-SKN - skin grafts for acute wounds

Data announced in June 2007 highlighted first artificial living skin graft to demonstrate full, consistent wound integration and persistence - a landmark in regenerative medicine
Follow up Phase I extension study shows continued integration of ICX-SKN at 3 months in all 6 subjects, with no evidence of rejection or wound breakdown
Phase II trial in basal-cell skin carcinoma excisions to commence in H2 2008
ICX-TRC - hair regeneration

Three and six month data from Phase II trial shows increase in hair count
Larger data set available in H2 2008
CORPORATE AND FINANCIAL HIGHLIGHTS

Placing of new shares in May 2007 raised £12m gross
Comprehensive supply agreement signed with Baxter Healthcare for use of Tisseel® in ICX-PRO and ICX-SKN
Milestone payment of US$200,000 received from Bosley under ICX-TRC option
Loss before tax for the year of £11.63m (2006: £9.23m)
Cash and cash equivalents and liquid investments at 31 December 2007 of £12.50m (2006: £10.99m)
Nick Higgins, CEO of Intercytex, commented: “Regenerative medicine, the restoration and repair of human tissues and organs, has the potential to revolutionise the treatment of patients. We now have a maturing portfolio of assets focused on skin and hair all demonstrating exciting clinical efficacy in large and growing markets. As the data continues to be reported for each of our products with highly encouraging results, it underscores the potential of our technology and the value of Intercytex in the rapidly developing field of regenerative medicine.”

There will be an analyst meeting to discuss the results today at 9.30am at the offices of Financial Dynamics at Holborn Gate, 26 Southampton Buildings, WC2A 1PB. For those unable to attend, there will be a live audio conference call, please call Claire Rowell on 0207 269 7285 for details.

Enquiries

For more information, contact:

Intercytex Group plc
Nick Higgins, Chief Executive Tel: 0161 904 4500
Richard Moulson, Chief Financial Officer Tel: 0161 904 4500

Financial Dynamics
David Yates Tel: 0207 269 7156
Lara Mott Tel: 0207 269 7182

Piper Jaffray Ltd

Will Carnwath Tel: 0203 142 8700

Notes for Editors

Intercytex is a leading regenerative medicine company developing innovative products to restore skin and hair. Intercytex is using its fully integrated cell technology platform to develop products that harness the innate ability of human cells to regenerate and repair the body.

Intercytex has four products in development:

ICX-PRO, designed to stimulate active repair in chronic wounds - in a Phase III trial for VLUs and a Phase II trial for DFUs
ICX-SKN, being developed as a durable and robust skin replacement – in a Phase I extension trial
VAVELTA®, a facial rejuvenation product already introduced to the UK market
ICX-TRC, a hair regeneration product – in a Phase II trial
All Intercytex’ products are derived from unmodified human cells.

Intercytex commenced operations in 2000 and currently employs around 80 staff. In addition to its head office in Cambridge, UK, it has GMP compliant clinical production facility plus research and development laboratories in Manchester, UK. Additional laboratories are located in Boston, US.

Intercytex’ shares trade on the Alternative Investment Market of the London Stock Exchange under the ticker symbol ICX.L and on the Open Market and the Xetra trading platform of the Frankfurt Stock Exchange under the symbol IGJ.F.

Additional information on the Company can be found at www.intercytex.com

Statements contained within this press release may contain forward-looking information or statements with respect to the financial condition, results of operations and business achievements/performance of Intercytex and certain of the plans and objectives of management of Intercytex with respect thereto. By their nature, forward-looking statements involve risks and uncertainties that may cause actual results to vary from those contained in the forward-looking statements. In some cases, you can identify such forward-looking statements by terminology such as ‘may’, ‘will’, ‘could’, ‘forecasts’, ‘expects’, ‘plans’, ‘anticipates’, ‘believes’, ‘estimates’, ‘predicts’, ‘potential’, ‘continue’ or similar expressions. A number of factors, including the satisfactory progress of research and development, could cause Intercytex’ actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements. Forward projections reflect management’s best estimates based on information available at the time of issue and are not a guarantee of future performance. Other than as required by applicable law, Intercytex does not undertake any obligation to update or revise any forward-looking information or statements to reflect events or circumstances after the date of this release.

The term “Intercytex” refers to Intercytex Group plc and its subsidiary undertakings.

View the full press release in PDF format (PDF, 100KB, opens in a new window).

This page includes links to documents in Portable Document File (PDF) format. To read PDF documents you may need to download the free Adobe Acrobat Reader. For PDF accessibility help, visit Access Adobe. These links will open in a new browser window.

Home · Disclaimer · Privacy Statement · Site Map

About ICXProductsInvestorsMediaKnowledge Centre


#5

Here’s a PDF but that does not contain the information either.

http://www.intercytex.com/icx/investors/rep/rep2008/2008-03-18/2008-03-18.pdf


#6

So? Any explanation??


#7

» So? Any explanation??

i think the previous links are wrong.
it is here, debris:

http://www.intercytex.com/icx/news/releases/2008/2008-03-18/2008-03-18.pdf

go to page 9/16

you can reach that document from here:
http://www.intercytex.com/icx/news/releases/2008/2008-03-18

and near the bottom, there is a link:
View the full press release in PDF format (PDF, 100KB, opens in a new window).